Shah Shivang S, Macharia Alex, Makale Johnstone, Uyoga Sophie, Kivinen Katja, Craik Rachel, Hubbart Christina, Wellems Thomas E, Rockett Kirk A, Kwiatkowski Dominic P, Williams Thomas N
Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
BMC Med Genet. 2014 Sep 9;15:93. doi: 10.1186/s12881-014-0093-6.
The relationship between glucose-6-phosphate dehydrogenase (G6PD) deficiency and clinical phenomena such as primaquine-sensitivity and protection from severe malaria remains poorly defined, with past association studies yielding inconsistent and conflicting results. One possibility is that examination of a single genetic variant might underestimate the presence of true effects in the presence of unrecognized functional allelic diversity.
We systematically examined this possibility in Kenya, conducting a fine-mapping association study of erythrocyte G6PD activity in 1828 Kenyan children across 30 polymorphisms at or around the G6PD locus.
We demonstrate a strong functional role for c.202G>A (rs1050828), which accounts for the majority of variance in enzyme activity observed (P=1.5×10⁻²⁰⁰, additive model). Additionally, we identify other common variants that exert smaller, intercorrelated effects independent of c.202G>A, and haplotype analyses suggest that each variant tags one of two haplotype motifs that are opposite in sequence identity and effect direction. We posit that these effects are of biological and possible clinical significance, specifically noting that c.376A>G (rs1050829) augments 202AG heterozygote risk for deficiency trait by two-fold (OR = 2.11 [1.12 - 3.84], P=0.014).
Our results suggest that c.202G>A is responsible for the majority of the observed prevalence of G6PD deficiency trait in Kenya, but also identify a novel role for c.376A>G as a genetic modifier which marks a common haplotype that augments the risk conferred to 202AG heterozygotes, suggesting that variation at both loci merits consideration in genetic association studies probing G6PD deficiency-associated clinical phenotypes.
葡萄糖-6-磷酸脱氢酶(G6PD)缺乏症与诸如伯氨喹敏感性和预防重症疟疾等临床现象之间的关系仍未明确界定,过去的关联研究结果不一致且相互矛盾。一种可能性是,在存在未被识别的功能性等位基因多样性的情况下,对单一基因变异的检测可能会低估真实效应的存在。
我们在肯尼亚系统地研究了这种可能性,对1828名肯尼亚儿童的红细胞G6PD活性进行了精细定位关联研究,涉及G6PD基因座或其附近的30个多态性位点 。
我们证明了c.202G>A(rs1050828)具有强大的功能作用(P = 1.5×10⁻²⁰⁰,加性模型),该变异占所观察到的酶活性变异的大部分。此外,我们还识别出了其他常见变异,它们独立于c.202G>A发挥较小的、相互关联的效应,单倍型分析表明,每个变异标记了两个单倍型基序之一,这两个基序在序列同一性和效应方向上相反。我们认为这些效应具有生物学和可能的临床意义,特别指出c.376A>G(rs1050829)使202AG杂合子出现缺乏性状的风险增加了两倍(OR = 2.11 [1.12 - 3.84],P = 0.014)。
我们的结果表明,c.202G>A是肯尼亚观察到的G6PD缺乏性状流行率的主要原因,但同时也确定了c.376A>G作为一种遗传修饰因子的新作用,它标记了一个常见单倍型,增加了202AG杂合子的风险,这表明在探索G6PD缺乏相关临床表型的遗传关联研究中,两个基因座的变异都值得考虑。